

PRODUCT DATASHEET

ChemiScreen™ CB₁ Cannabinoid Membrane Preparation

CATALOG NUMBER:	HTS019M	QUANTITY:	200 units
LOT NUMBER:	22C1504	VOLUME/CONCENTRATION	1 mL, 2 mg/mL

BACKGROUND: CB₁ is a GPCR that is expressed primarily in brain and nervous tissue, and mediates numerous CNS responses such as analgesia, appetite, cognition, memory and locomotor activity. A number of cannabinoid ligands bind to CB₁ and activate G_{i/o}-mediated downstream responses, including inhibition of cAMP production and activation of ion channels and MAP kinases. Ligands for CB₁ include exogenous agonists such as Δ⁹-THC, the main psychoactive component of the plant *Cannabis sativa*, and endogenous eicosanoid agonists such as anandamide. A number of synthetic agonists such as CP55940 and R-(+)-WIN55212, and antagonists, such as SR141716A, for CB₁ have been developed (Howlett *et al.*, 2002). CB₁ agonists have clinical utility in analgesia and antiemetic properties, whereas CB₁ antagonists show promise for treatment of appetite in obesity disorders. The CB₁ membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression. Thus, they are ideal HTS tools for screening for agonists and antagonists of CB₁. The membrane preparations exhibit a K_d of 2.15 nM for [³H]-CP55940. In the presence of 2 nM [³H]-CP55940 with WIN55212 as the unlabeled competitor, 10 μg/well of CB₁ Membrane Prep typically yields ≥2.5-fold signal-to-background ratio.

APPLICATIONS: Radioligand Binding Assay




Figure 1. Saturation Binding for CB₁. 7.5 μg/well of CB₁ Membrane Preparation was incubated with increasing amounts of [³H]-CP55940 in the absence (total binding, TB) or presence (nonspecific binding, NSB) of 5000-fold excess unlabeled WIN55212. Specific binding (SB) was determined by subtracting NSB from TB.




Figure 2. Competition Binding for CB₁. 7.5 µg/well of CB₁ Membrane was incubated with 2 nM [³H]-CP55940 and increasing concentrations of unlabeled CP55940 and were subjected to filtration binding. Greater than 1.5-fold signal:background ratio was obtained.

SPECIFICATIONS: 1 unit = 10 µg
 B_{max} for [³H]-CP55940 Binding: 3.055 pmol/mg protein
 K_d for [³H]-CP55940 Binding: 0.964 nM
Signal:Background: ≥2.5-fold

HOST CELLS: Chem-1, an adherent mammalian cell line without detectable endogenous CB₁ expression.

Species: Human CB₁ (Accession number X54937)

RECOMMENDED BINDING ASSAY CONDITIONS: Membranes were mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a non-binding 96-well plate and incubated for 30 min at room temperature. Prior to filtration, an FC 96-well harvest plate was coated with 0.3% polyethyleneimine. The binding reactions were transferred to the filter plate, and washed 7 times (1 mL per well per wash) with Wash Buffer. The wells were then dried and counted to determine receptor-associated radioligand binding.

Binding Buffer: 50 mM Tris/HCl, pH 7.4, 2.5 mM EDTA/Tris, 5 mM MgCl₂, 1 µg/ml Leupeptin, 1 µM Pepstatin, 10 µg/ml trypsin inhibitor, 0.3% BSA, stored at 4°C. Ligands were diluted in binding buffer containing 10% DMSO, and were then added to membranes such that the final DMSO concentration was 1%.

Radioligand: [³H]-CP55940 (PerkinElmer#: NET1051)

Wash Buffer: 50 mM Tris/HCl, pH 7.4, 0.5% BSA, stored at 4°C.

One vial contains enough membranes for at least 200 assays (units), where a unit is the amount of membrane that will yield approximately a 1.5-fold signal:background ratio with [³H]-CP55940 at 2 nM.

PRESENTATION:

Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol, and 1% BSA with no preservatives.

Packaging method: Membrane proteins were adjusted to 2 mg/mL in packaging buffer, dispensed at 1 mL per vial, rapidly frozen, and stored at -80°C.

**STORAGE/
HANDLING:**

Store at -70°C . Product is stable for at least 6 months from the date of receipt when stored as directed. Do not freeze and thaw this product.

REFERENCES:

1. Howlett AC *et al.* (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.* 54:161-202.

**FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES.
NOT FOR HUMAN OR ANIMAL CONSUMPTION.**

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

Eurofins Pharma Bioanalytics Services US Inc. is an independent member of Eurofins Discovery Services.